| 2023 |
| 02/03 | 15:30 特別損失の計上に関するお知らせ |
| 02/01 | 274 | 282 | 271 | 278 | +1.46% | 286,700 | 85億8217万 | +7.34% |
| 01/31 | 271 | 277 | 268 | 274 | +1.86% | 239,100 | 84億5869万 | +6.2% |
| 01/30 | 278 | 279 | 263 | 269 | -3.58% | 717,000 | 83億433万 | +5.08% |
| 01/27 | 282 | 285 | 275 | 279 | -1.41% | 290,500 | 86億1304万 | +9.41% |
| 01/26 | 296 | 297 | 280 | 283 | -3.41% | 879,300 | 87億3653万 | +11.42% |
| 01/25 | 271 | 305 | 271 | 293 | +6.93% | 2,660,900 | 90億4524万 | +15.81% |
| 01/24 | 260 | 286 | 255 | 274 | +6.61% | 2,276,400 | 84億5869万 | +9.16% |
| 01/23 | 252 | 262 | 250 | 257 | +3.21% | 536,500 | 78億4556万 | +2.39% |
| 01/20 | 244 | 251 | 240 | 249 | +2.05% | 547,700 | 76億134万 | -0.8% |
| 01/19 | 239 | 247 | 231 | 244 | 0% | 921,900 | 74億4870万 | -2.79% |
| 01/18 | 277 | 278 | 240 | 244 | +2.95% | 5,477,400 | 74億4870万 | -3.17% |
| 01/17 | 15:00 神経疼痛治療薬「DW-5LBT」の追加試験結果について |
| 01/17 | 243 | 245 | 236 | 237 | -1.25% | 130,300 | 72億3501万 | -5.95% |
| 01/16 | 246 | 249 | 240 | 240 | -4.76% | 139,800 | 73億2659万 | -5.14% |
| 01/13 | 256 | 257 | 249 | 252 | -1.18% | 92,700 | 76億9292万 | -0.4% |
| 01/12 | 257 | 259 | 252 | 255 | -1.16% | 77,000 | 77億8450万 | +0.39% |
| 01/11 | 255 | 263 | 255 | 258 | +2.38% | 145,700 | 78億7608万 | +1.57% |
| 01/10 | 251 | 256 | 246 | 252 | +0.4% | 121,800 | 76億9292万 | -0.79% |
| 01/06 | 243 | 251 | 241 | 251 | +1.62% | 121,300 | 76億6239万 | -1.57% |
| 01/05 | 253 | 257 | 243 | 247 | -3.14% | 160,800 | 75億4028万 | -3.52% |
| 01/04 | 262 | 262 | 252 | 255 | -2.67% | 154,600 | 77億8450万 | -1.16% |
| 2022 |
| 12/30 | 252 | 263 | 252 | 262 | +3.56% | 135,000 | 79億9819万 | +1.16% |
| 12/29 | 248 | 256 | 248 | 253 | -0.39% | 166,600 | 77億2345万 | -2.69% |
| 12/28 | 256 | 258 | 250 | 254 | -1.55% | 209,600 | 77億5397万 | -3.05% |
| 12/27 | 250 | 259 | 250 | 258 | +1.98% | 163,000 | 78億7608万 | -2.27% |
| 12/26 | 243 | 258 | 243 | 253 | +2.43% | 323,200 | 77億2345万 | -4.89% |
| 12/23 | 237 | 247 | 234 | 247 | +3.35% | 222,200 | 75億4028万 | -8.18% |
| 12/22 | 243 | 245 | 237 | 239 | -1.24% | 185,300 | 72億9606万 | -12.13% |
| 12/21 | 244 | 249 | 242 | 242 | -1.22% | 131,000 | 72億9119万 | -12% |
| 12/20 | 253 | 257 | 240 | 245 | -3.92% | 507,400 | 73億8158万 | -12.19% |
| 12/19 | 266 | 267 | 255 | 255 | -3.04% | 299,700 | 76億8287万 | -9.57% |
| 12/16 | 15:00 緑内障治療剤「H-1337」の米国後期第II相臨床試験の治験届提出のお知らせ |
| 12/16 | 261 | 267 | 260 | 263 | -0.75% | 133,100 | 79億2390万 | -7.39% |
| 12/15 | 255 | 267 | 253 | 265 | +3.92% | 321,500 | 79億8416万 | -7.02% |
| 12/14 | 255 | 259 | 254 | 255 | -1.16% | 172,500 | 76億8287万 | -11.15% |
| 12/13 | 258 | 264 | 252 | 258 | +1.98% | 395,700 | 77億7325万 | -11.03% |
| 12/12 | 15:00 ラクオリア創薬株式会社との共同研究契約締結のお知らせ |
| 12/12 | 252 | 253 | 249 | 253 | 0% | 158,800 | 76億2261万 | -13.36% |
| 12/09 | 251 | 257 | 248 | 253 | +1.2% | 258,100 | 76億2261万 | -14.24% |
| 12/08 | 260 | 260 | 248 | 250 | -3.47% | 507,700 | 75億3222万 | -16.39% |
| 12/07 | 283 | 288 | 254 | 259 | -0.38% | 2,316,400 | 78億338万 | -14.24% |
| 12/06 | 15:00 緑内障・高眼圧症治療剤「グラアルファ配合点眼液」国内販売開始のお知らせ |
| 12/06 | 267 | 267 | 260 | 260 | -1.89% | 184,400 | 78億3351万 | -14.47% |
| 12/05 | 268 | 270 | 263 | 265 | -1.12% | 153,600 | 79億8416万 | -13.96% |
| 12/02 | 273 | 274 | 263 | 268 | -1.47% | 259,900 | 80億7454万 | -13.55% |
| 12/01 | 273 | 279 | 270 | 272 | -0.73% | 242,600 | 81億9506万 | -12.82% |
| 11/30 | 278 | 278 | 269 | 274 | -2.14% | 387,100 | 82億5532万 | -12.74% |
| 11/29 | 279 | 285 | 277 | 280 | -1.41% | 203,300 | 84億3609万 | -11.39% |
| 11/28 | 293 | 295 | 280 | 284 | -3.4% | 442,400 | 85億5661万 | -10.69% |
| 11/25 | 301 | 303 | 294 | 294 | -2% | 355,100 | 88億5789万 | -7.84% |
| 11/24 | 308 | 308 | 297 | 300 | -1.64% | 375,000 | 90億3867万 | -6.25% |
| 11/22 | 304 | 311 | 303 | 305 | 0% | 303,700 | 91億8931万 | -4.98% |
| 11/21 | 339 | 342 | 304 | 305 | -7.01% | 1,072,000 | 90億5098万 | -4.98% |
| 11/18 | 15:30 当社子会社(日本革新創薬株式会社)の角膜内皮治療薬の実施権譲渡のお知らせ |
| 11/18 | 15:30 業績予想の修正に関するお知らせ |
| 11/18 | 325 | 335 | 321 | 328 | -0.91% | 394,600 | 97億3351万 | +2.18% |
| 11/17 | 338 | 357 | 323 | 331 | +3.76% | 2,276,100 | 98億2254万 | +3.76% |
| 11/16 | 15:00 緑内障・高眼圧症治療剤「グラアルファ配合点眼液」薬価収載のお知らせ |
| 11/16 | 327 | 328 | 319 | 319 | -1.54% | 185,800 | 94億6644万 | +0.31% |
| 11/15 | 320 | 328 | 317 | 324 | +0.62% | 200,100 | 96億1481万 | +1.89% |
| 11/14 | 308 | 327 | 305 | 322 | +4.55% | 359,700 | 95億5546万 | +1.26% |
| 11/11 | 297 | 313 | 296 | 308 | +1.65% | 269,300 | 91億4001万 | -3.75% |
| 11/10 | 15:30 2022年12月期第3四半期決算短信〔日本基準〕(連結) |
| 11/10 | 307 | 314 | 303 | 303 | -1.62% | 191,600 | 89億9163万 | -5.02% |
| 11/09 | 317 | 317 | 301 | 308 | -3.14% | 307,300 | 91億4001万 | -2.84% |
| 11/08 | 322 | 327 | 318 | 318 | -1.24% | 205,400 | 94億3676万 | +0.63% |
| 11/07 | 331 | 331 | 318 | 322 | -3.3% | 501,800 | 95億5546万 | +3.21% |
| 11/04 | 328 | 338 | 324 | 333 | -0.3% | 230,800 | 98億8189万 | +7.77% |
| 11/02 | 323 | 341 | 315 | 334 | +3.41% | 464,800 | 99億1157万 | +9.51% |
| 11/01 | 330 | 333 | 317 | 323 | -2.12% | 415,700 | 95億8514万 | +7.31% |
| 10/31 | 344 | 353 | 330 | 330 | -2.94% | 607,200 | 97億9287万 | +10.74% |
| 10/28 | 335 | 341 | 325 | 340 | +1.8% | 633,400 | 100億8962万 | +15.65% |
| 10/27 | 316 | 336 | 315 | 334 | +5.03% | 580,300 | 99億1157万 | +15.17% |
| 10/26 | 319 | 328 | 317 | 318 | 0% | 311,200 | 94億3676万 | +11.19% |
| 10/25 | 313 | 322 | 309 | 318 | +1.27% | 190,100 | 94億3676万 | +12.37% |
| 10/24 | 325 | 326 | 309 | 314 | -3.38% | 313,300 | 93億1806万 | +12.54% |
| 10/21 | 315 | 326 | 315 | 325 | +3.83% | 289,200 | 95億6566万 | +17.75% |
| 10/20 | 325 | 329 | 313 | 313 | -5.15% | 384,400 | 92億1246万 | +15.07% |
| 10/19 | 309 | 335 | 309 | 330 | +6.11% | 744,100 | 97億1282万 | +22.68% |
| 10/18 | 306 | 312 | 301 | 311 | +0.65% | 236,300 | 91億5360万 | +17.36% |
| 10/17 | 301 | 313 | 297 | 309 | +2.66% | 290,300 | 90億9473万 | +17.94% |
| 10/14 | 299 | 308 | 292 | 301 | +1.69% | 320,700 | 88億5927万 | +16.22% |
| 10/13 | 303 | 306 | 292 | 296 | -3.9% | 353,800 | 87億1210万 | +15.63% |
| 10/12 | 309 | 313 | 291 | 308 | -1.91% | 789,400 | 90億6530万 | +21.74% |
| 10/11 | 319 | 332 | 312 | 314 | -3.98% | 580,700 | 92億4189万 | +26.1% |
| 10/07 | 333 | 350 | 311 | 327 | -8.4% | 2,888,500 | 96億2452万 | +33.47% |
| 10/06 | 273 | 357 | 273 | 357 | +28.88% | 2,362,800 | 105億750万 | +48.13% |
| 10/05 | 281 | 284 | 267 | 277 | +0.73% | 553,500 | 81億5288万 | +17.87% |
| 10/04 | 15:00 神経疼痛治療薬「DW-5LBT」今後の見通しについて |
| 10/04 | 261 | 278 | 255 | 275 | +4.56% | 495,700 | 80億9402万 | +18.53% |
| 10/03 | 241 | 264 | 235 | 263 | +9.58% | 528,700 | 77億4082万 | +14.35% |
| 09/30 | 238 | 245 | 235 | 240 | -1.23% | 124,500 | 70億6387万 | +5.26% |
| 09/29 | 226 | 246 | 226 | 243 | +9.46% | 461,200 | 71億5217万 | +7.05% |
| 09/28 | 237 | 237 | 220 | 222 | -6.72% | 183,700 | 65億3408万 | -1.33% |
| 09/27 | 243 | 245 | 228 | 238 | -0.42% | 390,100 | 70億500万 | +5.78% |
| 09/26 | 15:30 緑内障・高眼圧症治療剤「K-232(販売名:グラアルファ配合点眼液)」の国内製造販売承認取得のお知らせ |
| 09/26 | 234 | 239 | 233 | 239 | +0.84% | 103,000 | 70億3443万 | +6.7% |
| 09/22 | 232 | 238 | 231 | 237 | +0.85% | 80,000 | 69億7557万 | +6.28% |
| 09/21 | 237 | 237 | 231 | 235 | -1.26% | 65,700 | 69億1670万 | +5.86% |
| 09/20 | 236 | 238 | 233 | 238 | +2.15% | 120,900 | 70億500万 | +7.69% |
| 09/16 | 238 | 238 | 231 | 233 | -0.85% | 61,500 | 68億5784万 | +5.91% |
| 09/15 | 240 | 241 | 235 | 235 | +1.29% | 118,400 | 69億1670万 | +7.31% |
| 09/14 | 225 | 233 | 225 | 232 | +1.31% | 53,100 | 68億2840万 | +6.42% |
| 09/13 | 236 | 238 | 229 | 229 | -1.72% | 73,100 | 67億4011万 | +5.05% |
| 09/12 | 237 | 241 | 233 | 233 | -2.1% | 90,900 | 68億5784万 | +7.37% |
| 09/09 | 241 | 242 | 230 | 238 | -0.83% | 233,300 | 70億500万 | +9.68% |
| 09/08 | 228 | 247 | 226 | 240 | +5.73% | 579,900 | 70億6387万 | +11.11% |
| 09/07 | 225 | 227 | 220 | 227 | +1.79% | 130,900 | 66億8124万 | +5.58% |
| 09/06 | 217 | 224 | 217 | 223 | +2.76% | 136,900 | 65億6351万 | +3.72% |
| 09/05 | 217 | 218 | 213 | 217 | +0.46% | 78,800 | 63億8691万 | +0.93% |
